Newly appointed BSC President Michael Mahoney.

J&J Medical Device and Diagnostics Worldwide Group Chairman Michael Mahoney was named Boston Scientific Corp (BSC) President, effective Oct 17, and is expected to become BSC's CEO on Nov 1, 2012.

The transition period is being implemented to accommodate Mahoney's post-employment obligations to Johnson & Johnson, which both Boston Scientific and Johnson & Johnson have agreed is appropriate. Ray Elliott, who announced last May that he would step down as president and CEO, will do so on Oct 17, 2011. At that time, Hank Kucheman, currently the executive vice president and group president of the Cardiology, Rhythm and Vascular (CRV) Group, Boston Scientific's largest business, will be promoted to serve as interim CEO until Mahoney assumes the role. As president, Mahoney will report to Kucheman. In connection with his promotion to CEO, Kucheman will be appointed to the company's board of directors. Elliott will be available to assist Kucheman and Mahoney through the end of the year, at which time he will retire, and remain and active BSC board member.

Mahoney's health experience in medical devices spans 22 years. As BSC president, his initial responsibilities will focus on the oversight of Cardiac Rhythm Management (CRM) and Endoscopy (GI and Pulmonary), as well as corporate functions. On Aug 1, 2012, Mahoney will assume responsibility for Neuromodulation.